EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC 4.0

Ceramide‐based risk score CERT‐1 improves risk prediction for overall mortality and adverse cardiovascular outcomes in patients with and without cardiovascular disease: A prospective cohort study

Alessandro Mantovani, Gianluigi Lunardi, Stefano Bonapace, Agustin E Molinero, Riccardo Morandin, Veronica Fiorio, Giulio Molon, Christopher D Byrne iD, Giovanni Targher iD

Diabetes, Obesity and Metabolism · 2025-03 · 27 (3) · 1488-1497

DOI: 10.1111/dom.16156 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 26.12.2024. Verfasst von Alessandro Mantovani und 8 weiteren Autor:innen. Beteiligte Einrichtung: Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University and Azienda Ospedaliera Universitaria Integrata of Verona, Vero…. Hauptthemen laut MEDLINE: Ceramides, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Diabetic Angiopathies. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Whether the plasma‐based ceramide‐based risk score CERT1 improves risk prediction for cardiovascular disease (CVD) is uncertain. Materials and Methods Baseline and follow‐up data were combined from two cohorts, 334 patients with established/suspected CVD and 196 patients with type 2 diabetes followed for a median of 74 months (interquartile range 54–79 months). For the calculation of CERT1 risk score, we measured four specific plasma ceramides [Cer(d18:1/16:0), Cer(d18:1/18:0) and Cer(d18:1/24:1)] and their ratios to Cer(d18:1/24:0). Based on the CERT1 risk score, patients were split into four risk categories (low, moderate, increased or high risk). The primary outcome was a composite of overall mortality and incident nonfatal CVD outcomes (including myocardial infarction, ischaemic stroke or permanent atrial fibrillation).

Results

One hundred and thirty‐nine patients developed the primary composite outcome (72 nonfatal CVD outcomes and 67 total deaths) during follow‐up. Baseline CERT1 risk categories were significantly associated with the risk of developing the primary composite outcome (adjusted HR for high vs. low‐risk category 2.43, 95% CI 1.39–4.22, p = 0.002, and adjusted HR for increased vs. low‐risk category 2.16, 95% CI 1.28–3.63, p = 0.004). Receiver operator characteristic curve analysis showed that adding CERT1 risk score to traditional CVD risk factors and pre‐existing CVD, improved the discriminatory capability of the regression model for predicting the primary composite outcome (AUROC 0.691 [95% CI 0.674–0.769] vs. 0.722 [95% CI 0.642–0.742], p = 0.0275).

Conclusions

The ceramide‐based risk score CERT1 risk score improves risk prediction for long‐term risk of overall mortality and adverse cardiovascular outcomes in patients with and without CVD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CeramidesCardiovascular DiseasesDiabetes Mellitus, Type 2Diabetic AngiopathiesHumansFemaleMaleMiddle AgedProspective StudiesAgedRisk AssessmentRisk FactorsBiomarkersPrognosisPredictive Value of TestsFollow-Up Studies

Stichwörter der Autor:innen

CERT1 scoreCVDcardiovascular morbiditymortalityplasma ceramides

Substanzen

CeramidesBiomarkers

Autor:innen und Institutionen

  • Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy.
  • Clinical Analysis Laboratory and Transfusional Medicine, Clinical Pharmacology, "IRCCS Sacro Cuore - Don Calabria" Hospital, Negrar di Valpolicella, Italy.
  • Division of Cardiology, IRCCS Sacro Cuore-Don Calabria Hospital, Negrar di Valpolicella, Italy.
  • Southampton National Institute for Health Research Biomedical Research Centre, University Hospital Southampton, Southampton General Hospital, Southampton, UK.
  • Nutrition and Metabolism, Faculty of Medicine, University of Southampton, Southampton, UK.
  • Department of Medicine, University of Verona, Verona, Italy.

ORCID-Profile: Christopher D Byrne, Giovanni Targher

Zitieren

APA

Mantovani, A., Lunardi, G., Bonapace, S., Molinero, A. E., Morandin, R., Fiorio, V., Molon, G., Byrne, C. D., & Targher, G. (2025). Ceramide‐based risk score CERT‐1 improves risk prediction for overall mortality and adverse cardiovascular outcomes in patients with and without cardiovascular disease: A prospective cohort study. Diabetes, Obesity and Metabolism, 27(3), 1488-1497. https://doi.org/10.1111/dom.16156

Vancouver

Mantovani A, Lunardi G, Bonapace S, Molinero AE, Morandin R, Fiorio V, et al. Ceramide‐based risk score CERT‐1 improves risk prediction for overall mortality and adverse cardiovascular outcomes in patients with and without cardiovascular disease: A prospective cohort study. Diabetes, Obesity and Metabolism. 2025;27(3):1488-1497. doi:10.1111/dom.16156

BibTeX
@article{Mantovani2025,
  author = {Mantovani, Alessandro and Lunardi, Gianluigi and Bonapace, Stefano and Molinero, Agustin E and Morandin, Riccardo and Fiorio, Veronica and Molon, Giulio and Byrne, Christopher D and Targher, Giovanni},
  title = {Ceramide‐based risk score CERT‐1 improves risk prediction for overall mortality and adverse cardiovascular outcomes in patients with and without cardiovascular disease: A prospective cohort study},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2025},
  volume = {27},
  number = {3},
  pages = {1488--1497},
  doi = {10.1111/dom.16156}
}
Kostenlos starten →